Track First Tracks Biotherapeutics Inc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

First Tracks Biotherapeutics Inc TRAX · Stock Open First Tracks Biotherapeutics Inc in new tab

47.10 USD
EPS
-4.71
P/B
11.20
Target Price
75.17 USD
Loading chart...
Key Metrics
Earnings dateFeb. 2, 2027
EPS-4.71
Book Value4.21
Price to Book11.20
Debt/Equity2.50
% Insiders3.667%
Estimates
Forward P/E-13.42
Forward EPS-3.51
Target Mean Price75.17

DCF valuation

Model fair value for First Tracks Biotherapeutics Inc (TRAX)
Result
Sign in to run the valuation for TRAX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 75.17 USD (low 57.00, high 110.00) · as of 14 Nov 2026
Low 57.00
Mean 75.17
High 110.00
Price 47.10
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

First Tracks Biotherapeutics Inc Logo First Tracks Biotherapeutics Inc Analysis (TRAX)

US Healthcare Official Website Stock

Is First Tracks Biotherapeutics Inc a good investment? First Tracks Biotherapeutics Inc (TRAX) is currently trading at 47.10 USD. Market analysts have a consensus price target of 75.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: First Tracks Biotherapeutics Inc is expected to release its next earnings report on Feb. 2, 2027. The market consensus estimate for Forward EPS is -3.51.

Investor FAQ

Does First Tracks Biotherapeutics Inc pay a dividend?

No, it does not currently pay a dividend.

What asset class is First Tracks Biotherapeutics Inc?

First Tracks Biotherapeutics Inc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 2, 2027. The company currently has a trailing EPS of -4.71.

Company Profile

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Exchange Ticker
NASDAQ TRAX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion